Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis

Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis

IntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-1 (PD-L1) expression (≧50%). Pre-treatment or post...

Full description

Bibliographic Details
Main Authors: Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Immunology
Subjects:
soluble PD-L1
advanced non-small cell lung cancer
PD-1 inhibitors
individual patient data meta-analysis
biomarker
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1308381/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1308381/full

Similar Items